Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Cancer
100%
Prostatectomy
30%
Androgen Deprivation Therapy
20%
Overall Survival
19%
Cohort Analysis
17%
Cancer Mortality
16%
Prostate Specific Antigen
16%
Randomized Controlled Trial
16%
Clear Cell Renal Cell Carcinoma
16%
Thyroid Gland
14%
Liotrix
12%
Thyroid Hormone
12%
Elderly Patient
12%
Prognostic Factor
10%
Hypothyroidism
10%
Urinary System
10%
Reoperation
10%
Tumor
10%
Retrospective Cohort Study
9%
Continence
9%
Robot-Assisted Prostatectomy
9%
Hazard Ratio
9%
Bladder Cancer
9%
Cancer Screening
9%
Cancer Diagnosis
9%
Magnetic Resonance Imaging
9%
Screening of Prostate Cancer
9%
Mammography
9%
Breast Cancer
9%
Randomized Clinical Trials
9%
Neoplasm
8%
Cystectomy
8%
Lower Urinary Tract Symptom
8%
Kidney Cancer
8%
Nonsteroid Antiinflammatory Agent
8%
Asymptomatic Bacteriuria
8%
Big Data
8%
Cancer Survival
8%
Comorbidity
7%
Quality of Life
7%
Cancer Therapy
7%
Health Care Cost
7%
Malignant Neoplasm
6%
Median Follow Up
6%
Recurrent Disease
6%
Diseases
6%
Genetics
6%
Arm
6%
Biopsy Technique
6%
Castration Resistant Prostate Cancer
5%
Visual Analog Scale
5%
Acetylsalicylic Acid
5%
Proportional Hazards Model
5%
Immunotherapy
5%
Conservative Treatment
5%
Survival Rate
5%
Hernioplasty
5%
Cancer Specific Survival
5%
Radiation Therapy
5%
Specific Mortality
5%
Darolutamide
5%
Keyphrases
Prostate Cancer
42%
Prostate Cancer Risk
23%
Prostate Cancer Screening
21%
Finland
20%
Androgen Deprivation Therapy
16%
95% Confidence Interval
16%
European Randomized Study of Screening for Prostate Cancer
15%
Prostate-specific Antigen
13%
Population-based Cohort
10%
Risk of Death
10%
EPIC-26
10%
Risk Factors
10%
Expanded Prostate Cancer Index Composite
10%
High-grade Prostate Cancer
10%
Breast Cancer
9%
Tolerability
9%
Total Prostate-specific Antigen
9%
Hazard Ratio
9%
Cancer-specific Survival
8%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
8%
Randomized Trial
8%
Three-dimensional (3D)
8%
Euthyroid
8%
Lower Urinary Tract Symptoms
8%
Aggregate Data
8%
Population-based Study
8%
Localized Prostate Cancer
8%
Penile Cancer
8%
Renal Cancer
8%
Bacillus
8%
Renal Cell Carcinoma
8%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8%
Finnish Population
8%
Clear Cell Renal Cell Carcinoma (ccRCC)
8%
Cancer Detection
8%
Bacillus Calmette
7%
Prostate-specific Antigen Testing
7%
Tumor
7%
Cancer Mortality
7%
Oncological Outcomes
7%
Metastatic Prostate Cancer
7%
Age Groups
6%
Bladder Cancer
6%
Overall Survival
6%
Prostate Radiotherapy
6%
Asymptomatic Bacteriuria
6%
Diagnostic Support
6%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
6%
Acetylsalicylic Acid
6%
Adverse Events
6%
Hypothyroidism
5%
Visual Analog Scale
5%
University Hospital
5%
Drug Use
5%
Non-muscle Invasive Bladder Cancer (NMIBC)
5%
Random Forest Algorithm
5%
Retrospective Cohort Study
5%
High Risk
5%
Control Arm
5%
Low-risk Prostate Cancer
5%
Breast Cancer Survival
5%
Aggressive Prostate Cancer
5%
Cumulative Incidence
5%
Randomized Clinical Trial
5%
Darolutamide
5%
Europe
5%
International Survey
5%
Levothyroxine
5%
Surgical Outcomes
5%
Early Detection
5%
Long-run Risk
5%
Single Center
5%
Screen-detected
5%
Odds Ratio
5%